MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Amarin Corporation plc DPO Ratio 2011-2026 | AMRN
Annual DPO Ratio Amarin Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 190 | 252 | 204 | 64.4 | 142 | 152 | 196 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 252 | 64.4 | 171 |
Quarterly DPO Ratio Amarin Corporation plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 422 | - | 323 | 334 | 322 | - | 292 | 335 | 204 | - | 179 | 200 | 233 | - | 254 | 267 | 269 | - | 193 | 201 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 422 | 179 | 269 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B |  USA |
 |
Heron Therapeutics
HRTX
|
91.4 | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Incyte Corporation
INCY
|
200 | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
129 | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
Clovis Oncology
CLVS
|
236 | - | -7.23 % | $ 13 M | USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
CorMedix
CRMD
|
79.3 | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
106 | $ 8.33 | 0.97 % | $ 260 M | Israel |